Quanterix Corporation

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the “Inducement Grants”) were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute consisted of 260,315 restricted stock Units (“RSUs”) representing 260,315 shares of Qua.

Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has b

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company's Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix's innovative technologies and application.

BlackRock Inc. bought a new position in shares of Quanterix Corporation (NASDAQ: QTRX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,635,411 shares of the company's stock, valued at approximately $15,705,000. BlackRock Inc. owned about 7.72% of Quanterix as of its